Screening for basiliximab exposure-response relationships in renal allotransplantation

Clinical Transplantation

Volumn 13, Issue 1 I, 1999, Pages 32-38

  Kovarik, J M ^a   Moore, R ^b   Wolf, P ^c   Abendroth, D ^d   Landsberg, D ^e   Soulillou, J P ^f   Gerbeau, C ^g   Schmidt, A G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Cardiff Royal Infirmary   (United Kingdom)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e ST PAUL S HOSPITAL   (Canada)

^f HÔTEL DIEU   (France)

^g NOVARTIS PHARMA K K   (Japan)

Author keywords

Acute rejection; Immunosuppression; Interleukin 2 receptor; Monoclonal antibodies; Renal transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032983478     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.1999.t01-2-130105.x     Document Type: Article

References (11)

1. SOULILLOU J-P. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994: 46: 540-553.
2. AMLOT PL, RAWLINGS E, FERNANDO ON, GRIFFIN PJ, HEINRICH G, SCHREIER MH et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995: 60: 748-756.
3. KOVARIK JM, WOLF P, CISTERNE JM, MOURAD G, LEBRANCHU Y, LANG P et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997: 64: 1701-1705.
4. BASADONNA GP, MATAS AJ, GlLLINGHAM KJ, PAYNE WD, DUNN DL, SUTHERLAND DER et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993: 55: 993-995.
5. NASHAN B, MOORE R, AMLOT P, SCHMIDT AG, ABEYWICKRAMA K, SOULILLOU JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997: 350: 1193-1198.
6. BEAL SL, SHEINER LB, NONMEM User's Guide. NONMEM Project Group: University of California at San Francisco, San Francisco, CA, USA 1991.
7. LANDAW EM, DISTEFANO JJ. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 1984: 246: R665-R677.
8. BASILIXIMAB PRODUCT MONOGRAPH. Novartis Pharmaceuticals Corp.: East Hanover, NJ 1998.
9. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDICK JF, COHEN AH, COLVIN RB et al. International standarization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411-422.
10. TRANG JM. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: FERRAIOLO BL. ed. Protein Pharmacokinetics and Metabolism. New York: Plenum Press. 1992: 223-271.
11. AMLOT PL. Clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: CHATENOUD L. ed. Monoclonal Antibodies in Transplantation. New York: Springer. 1995: 53-98.